Advanced Biomed Inc. Common Stock logo

Advanced Biomed Inc. Common Stock(ADVB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.53
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ADVB

11/13/2026: ADVB (1-star) is currently NOT-A-BUY. Pass it for now.

Advanced Biomed Inc. is a micro-cap medical technology holding company that develops microfluidic biochip systems and automated testing equipment for precision oncology and cancer detection. The company's primary strengths lie in its proprietary integration of semiconductor manufacturing techniques with rare cell separation technologies. Its main investment story revolves around potential growth in the expanding liquid biopsy and early cancer screening market. However, significant risks include intense competition from well-established diagnostics leaders, pre-profit operational losses, and high stock price volatility. The stock may suit speculative growth investors willing to monitor clinical adoption milestones and ongoing capital requirements closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks the steady revenue expansion and commercial scale required for a traditional growth profile.
Momentum investorStrong fit while signal remains positiveLow float micro-cap status can trigger sharp speculative price swings when trading volume spikes.
Value investorWeak fitUnprofitable operations and sparse fundamental metrics make traditional value assessment difficult.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into basic operations.
Low-risk investorWeak fitHigh price volatility, micro-cap liquidity risks, and lack of earnings create substantial downside exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThin trading volume and small market capitalization frequently cause severe intraday and historical price swings.
Valuation riskHighShare pricing can detach significantly from underlying financial realities due to speculative micro-cap dynamics.
Competition risk (diagnostics and liquid biopsy competition)HighWell-funded industry competitors dominate testing standards and clinical relationships.
Business qualityMediumInnovative microfluidic technology is offset by early commercial maturity and unproven scale.
Dividend incomeLow / noneNo cash returns are distributed to shareholders through payouts.
Execution riskHighSuccess relies entirely on achieving regulatory milestones and commercial adoption with limited capital.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.18M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 65.3K shares
Beta -
52 Weeks Range 1.80 - 24.23
Updated Date 11/15/2026
52 Weeks Range 1.80 - 24.23
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 52.41%
Avg. Invested days 7
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ADVB receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
ADVB has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+304.9%) and strong profitability (net margin 5231.3%) are partially offset by weak cash generation (FCF margin -1525.4%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ADVB's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is ADVB's strongest growth driver at +304.9% FY2026 versus FY2025 (strong, 5 stars). By comparison, free-cash-flow growth (+66.8%, strong) is also strong, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 5.1% and approximately 59.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 61.41% supports management-shareholder alignment.

Top 5 Institutional Investors

Renaissance Technologies Corp 0.64%

Unit Economics (Per $1K Revenue)

★★★★★
ADVB generates approximately $-48,838 of gross profit, $-48,838 of operating income, and $-15,254 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.02%

Quantitative Style Profile

★★★★★
ADVB has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Microfluidic Biochips and Diagnostic DevicesSales of specialized testing equipment such as A+Pre, AC-1000, A+SCDrop, and accompanying biochips and dye kits.Revenue depends on selling specialized hardware and consumable biochips to laboratories or medical partners.
Regional Operations (Taiwan and Asia)Research, development, and commercial outreach anchored in Taiwan and regional Asian markets.Operations are heavily concentrated overseas, exposing the firm to regional regulatory and market conditions.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.61M
Price to Sales(TTM) 32.75
Enterprise Value 1.61M
Price to Sales(TTM) 32.75
Enterprise Value to Revenue 12.59
Enterprise Value to EBITDA -
Shares Outstanding 1.65M
Shares Floating 986.29K
Shares Outstanding 1.65M
Shares Floating 986.29K
Percent Insiders 61.41
Percent Institutions 5.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.